Manulife (Manufacturers Life Insurance)
FDMT icon

Manulife (Manufacturers Life Insurance)’s 4D Molecular Therapeutics FDMT Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$166K Buy
12,489
+233
+2% +$2.27K ﹤0.01% 2626
2026
Q1 		$114K Sell
12,256
-339
-3% -$2.95K ﹤0.01% 2595
2025
Q4 		$94.5K Sell
12,595
-1,687
-12% -$17.1K ﹤0.01% 2713
2025
Q3 		$124K Sell
14,282
-567
-4% -$3.39K ﹤0.01% 2730
2025
Q2 		$55.1K Sell
14,849
-3,743
-20% -$13.2K ﹤0.01% 2875
2025
Q1 		$60.1K Buy
18,592
+115
+0.6% +$542 ﹤0.01% 2804
2024
Q4 		$103K Buy
18,477
+56
+0.3% +$439 ﹤0.01% 2813
2024
Q3 		$199K Sell
18,421
-554
-3% -$9.19K ﹤0.01% 2672
2024
Q2 		$398K Buy
18,975
+3,850
+25% +$96.6K ﹤0.01% 2304
2024
Q1 		$482K Buy
15,125
+180
+1% +$4.59K ﹤0.01% 2229
2023
Q4 		$303K Hold
14,945
– – ﹤0.01% 2408
2023
Q3 		$190K Buy
14,945
+2,232
+18% +$37.3K ﹤0.01% 2629
2023
Q2 		$230K Buy
12,713
+689
+6% +$12.7K ﹤0.01% 2531
2023
Q1 		$207K Hold
12,024
– – ﹤0.01% 2547
2022
Q4 		$267K Sell
12,024
-599
-5% -$9.25K ﹤0.01% 2379
2022
Q3 		$101K Sell
12,623
-451
-3% -$4.08K ﹤0.01% 2804
2022
Q2 		$91.3K Buy
13,074
+1,294
+11% +$12.6K ﹤0.01% 2936
2022
Q1 		$178K Sell
11,780
-2,054
-15% -$32.3K ﹤0.01% 2816
2021
Q4 		$304K Buy
13,834
+2,656
+24% +$65.1K ﹤0.01% 2596
2021
Q3 		$301K Buy
+11,178
New +$319K ﹤0.01% 2665

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Manulife (Manufacturers Life Insurance)'s FDMT Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) increased its 4D Molecular Therapeutics (FDMT) stake by 1.9% in Q2 2026, buying an estimated $2.27K and bringing the position to 12,489 shares worth $166K. The position accounts for ﹤0.01% of the portfolio, ranked #2626.

Manulife (Manufacturers Life Insurance) first reported a position in FDMT in Q3 2021 and has held it in 20 quarters since. The position peaked at $482K in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 12,489 shares of 4D Molecular Therapeutics worth $166K as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) bought 233 4D Molecular Therapeutics shares in Q2 2026, an estimated $2.27K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #2626 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in 4D Molecular Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Manulife (Manufacturers Life Insurance)'s 4D Molecular Therapeutics position peaked at $482K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.